DSM, private equity firm JLL buy drugmaker Patheon for $195 million, will create new company

AMSTERDAM – Dutch chemicals maker Royal DSM NV and private equity firm JLL are teaming up to buy Canada’s Patheon Inc. for $195 million (145 million euros) so they can combine it with DSM’s pharmaceuticals arm and then spin off the new combination as a separate company.

Under the deal announced Tuesday, JLL will contribute $489 million to the new company, with the funds used to buy Patheon and pay DSM $200 million. After the deal, JLL will own 51 per cent of the new entity, and DSM will own 49 per cent.

Patheon’s managers, who own a majority of their company, have agreed to the firms’ $9.32 per share takeover offer. That’s a 64 per cent premium to Patheon’s closing price Monday.